U.S. emergency approval broadens use of Gilead’s COVID-19 drug remdesivir
During these trying times, good news is always welcome and should be shared. We are humbled and proud to announce that Gilead Sciences one of Chemical Safety Software’s oldest and most important clients, has been granted approval by the U.S. Food and Drug Administration (FDA) for their experimental Covid-19 treatment called Remdesivir.
During a meeting in the Oval Office of the White House with President Donald Trump, Gilead Chief Executive Daniel O’Day called the move an important first step and said the company was donating 1.5 million vials of the drug to help patients. The donation is expected to be enough for at least 140,000 patients, depending on the number of days they need to be treated.
Gilead (NASDQ GILD) said the drug, which is given by intravenous infusion, had helped improve outcomes for patients with COVID-19, the respiratory disease caused by the novel coronavirus, and provided data suggesting it worked better when given earlier in the course of infection.
We applaud Gilead’s efforts and join all of us in hearing more good news on this new treatment option.